VJHemOnc Podcast
Highlights in MDS at ASH 2022: treating lower-risk & higher-risk disease, trial updates, & more
Dec 21, 2022
Doctors David Sallman and Andrew Brunner discuss updates in myelodysplastic syndromes at ASH 2022. Topics include treatment options for lower-risk and higher-risk disease, trial updates, novel classification systems, and therapies after failure to hypomethylating agents.
14:26
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Therapies like luspatercept and metal stats show promise in treating lower-risk myelodysplastic syndrome (MDS) and may challenge traditional management approaches.
- Four large phase three randomized trials may offer new agents and redefine high-risk MDS, incorporating molecular diagnostics for better prognostication and treatment approaches.
Deep dives
Key Updates in Lower Risk MDS
The podcast discusses key updates in lower risk myelodysplastic syndrome (MDS). The experts mention the use of therapies like luspatercept and the promising data on the long-term responders with a metal stat. They also raise questions about the Cintra Rev trial, which challenges the typical management of lower risk MDS by introducing preemptive therapy. The experts acknowledge the need for disease modification in lower risk MDS and highlight ongoing trials with Kenna Kinumab, an interleukin one beta inhibitor, and explore the potential of lower schedules of hypomethylating agents as treatment options.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
